Atorvastatin use in specific populations: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 10: | Line 10: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
{{FDA}} | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drugs]] |
Revision as of 21:16, 30 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Hepatic impairment: Plasma concentrations markedly increased in patients with chronic alcoholic liver disease.[1]
References
Adapted from the FDA Package Insert.